Omnicell, Inc. (NASDAQ:OMCL) Stock Has Consensus Target Price of $57.86

Shares of Omnicell, Inc. (NASDAQ:OMCL) have earned a consensus recommendation of “Moderate Buy” from the nine brokerages that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $57.86.

Several equities analysts have recently commented on the stock. Weiss Ratings upgraded shares of Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 18th. Zacks Research raised shares of Omnicell from a “strong sell” rating to a “hold” rating in a report on Monday, September 7th. KeyCorp reiterated an “overweight” rating on shares of Omnicell in a research report on Monday, August 24th. Piper Sandler reissued an “overweight” rating and issued a $45.00 price objective (down from $55.00) on shares of Omnicell in a research note on Monday, August 3rd. Finally, Wells Fargo & Company decreased their price objective on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st.

Omnicell Stock Up 2.9%

Shares of NASDAQ OMCL opened at $36.87 on Friday. The stock has a market capitalization of $1.68 billion, a P/E ratio of 43.89, a PEG ratio of 0.90 and a beta of 0.98. The stock’s fifty day moving average is $34.64 and its 200 day moving average is $38.47. Omnicell has a 52 week low of $29.06 and a 52 week high of $55.00. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.43 and a current ratio of 1.64.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.47. The business had revenue of $312.21 million during the quarter, compared to analysts’ expectations of $310.21 million. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. Omnicell’s revenue was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.45 earnings per share. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Sell-side analysts forecast that Omnicell will post 1.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Omnicell

A number of large investors have recently modified their holdings of OMCL. Public Employees Retirement System of Ohio bought a new stake in Omnicell during the 2nd quarter worth $2,253,000. BlackRock Inc. bought a new position in Omnicell in the second quarter valued at about $313,044,000. Bank of America Corp DE raised its position in Omnicell by 31.3% in the first quarter. Bank of America Corp DE now owns 580,875 shares of the company’s stock valued at $19,390,000 after purchasing an additional 138,537 shares during the last quarter. Trillium Asset Management LLC bought a new position in Omnicell in the second quarter valued at about $4,816,000. Finally, Squarepoint Ops LLC boosted its stake in shares of Omnicell by 80.8% during the second quarter. Squarepoint Ops LLC now owns 120,419 shares of the company’s stock valued at $5,000,000 after purchasing an additional 53,807 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc provides medication-management technology and related services for health care providers. Its solutions are designed to help hospitals, health systems, retail pharmacies and other care settings manage medication inventory, improve workflow efficiency and support medication adherence.

The company’s offerings include automated medication dispensing systems, central pharmacy automation, medication packaging and adherence solutions, pharmacy inventory management tools, and software for medication-use analytics and workflow management.